08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuropathy Glial cell line-derived neurotrophic factor family receptor a1 (GFRA1) Studies in...
08:00 , Dec 13, 2010 |  BioCentury  |  Strategy

Unwinding Biovail's Deals

Unwinding Biovail's Deals Deal date Partner Product Product description Product status Deal status Deal terms Jun-10 Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) Istradefylline Adenosine A2A...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Glial derived neurotrophic factor: Development discontinued

Valeant said it will not pursue further development of preclinical candidate BVF-014 for PD. Valeant said the program, which it gained through its merger with Biovail Corp. this year, did not fit with the...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Glial cell-derived neurotrophic factor (GDNF); glial cell line-derived neurotrophic factor family receptor a1 (GFRA1); ret proto-oncogene...
08:00 , Feb 14, 2005 |  BC Week In Review  |  Clinical News

Glial derived neurotrophic factor: Phase II halted

AMGN stopped an open-label extension of a Phase II trial of 48 patients with advanced PD after new preclinical data showed that the compound caused irreversible cerebellar lesions in non-human primates. Data from the trial,...
07:00 , Jul 5, 2004 |  BC Week In Review  |  Clinical News

Glial derived neurotrophic factor: Phase II data

AMGN said in a double-blind Phase II trial in 34 patients, GDNF failed to meet the primary endpoint at 6 months. Patients who received daily infusions of 15 mg of GDNF into the putamen region...